Dr Marko Hyvonen
Position: Lecturer
Personal home page:
http://www-cryst.bioc.cam.ac.uk/groups/hyvonen
PubMed journal articles - click here
Dr Marko Hyvonen is pleased to consider applications from prospective PhD students.
We are using fragment based drug discovery methods to target a traditionally difficult class of drug targets, with emphasis on inhibition of protein-protein interactions critical to signalling proteins. We are also studying TGF-beta family growth factors, using biochemical, biophysical and structural biology approches to gain understanding on how they interact with regulatory proteins and receptors.
Symplectic Elements feed provided by Research Information, University of Cambridge
G. Fischer, M. Rossmann, M. Hyvönen. Alternative Modulation of Protein-Protein Interactions by Small Molecules. Curr Opin in Biotech (2015), pp. 78-85 DOI: 10.1016/j.copbio.2015.04.006 D.E. Scott, A. G. Coyne, T. L. Blundell, A. Venkitaraman, C. Abell, M. Hyvönen, Small molecule inhibitors targeting protein-protein interaction in the RAD51 family of recombinases, ChemMedChem, DOI: 10.1002/cmdc.201402428, 2014 D. E. Scott, M. T. Ehebauer, T. Pukala, M. Marsh, T. L. Blundell, A. R. Venkitaraman, C. Abell, M. Hyvönen. Targeting the RAD51:BRCA2 Protein-Protein Interaction using Fragment-based methods. ChemBioChem 14(3):332-42, 2013 P Sled?, C. J. Stubbs, S. Lang, Y. Q. Yang, G. J. McKenzie, A. R. Venkitaraman, M. Hyvönen, C Abell. From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of polo-like kinase 1. Angew Chem Int Ed Engl. 50:4003-6, 2011 A.E. Harrington, S.A. Morris-Triggs, B.T. Ruotolo, C.V. Robinson, S. Ohnuma and M. Hyvönen.. Structural basis for the inhibition of activin signalling by follistatin EMBO J, 25:1035-1045, 2006.
